Adlina-EM Tablet 10 mg + 5 mg is a combination oral antidiabetic medication formulated with Empagliflozin 10 mg and Linagliptin 5 mg. This dual-action tablet is designed for adults with type 2 diabetes mellitus who require enhanced glycemic control that cannot be achieved with diet, exercise, or single-drug therapy alone. By combining two complementary mechanisms, Adlina-EM helps manage blood glucose more effectively while also offering cardiovascular and metabolic benefits.

Adlina-EM is intended to be used alongside a balanced diet, regular physical activity, and routine monitoring of blood glucose levels. It provides the convenience of taking two effective antidiabetic agents in a single tablet, improving adherence to therapy.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

• Empagliflozin 10 mg

• Linagliptin 5 mg

Mechanism of Action

Adlina-EM combines the actions of an SGLT2 inhibitor and a DPP-4 inhibitor, targeting multiple pathways of glucose regulation:

Empagliflozin
Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that blocks glucose reabsorption in the kidneys. This increases urinary glucose excretion, lowering both fasting and postprandial blood glucose levels. It also contributes to modest weight reduction and may help lower blood pressure through osmotic diuresis.

Linagliptin
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases levels of incretin hormones (GLP-1 and GIP). These hormones stimulate glucose-dependent insulin secretion and suppress glucagon release after meals, improving glycemic control without significantly increasing the risk of hypoglycemia.

By combining these two mechanisms, Adlina-EM offers comprehensive glycemic control, addressing both glucose overproduction and impaired insulin response.

Indications

Adlina-EM Tablet 10 mg + 5 mg is indicated for:

• Management of Type 2 Diabetes Mellitus in adults

• Patients inadequately controlled with diet, exercise, or single-drug therapy

• Combination therapy for improved glycemic control when monotherapy with empagliflozin or linagliptin is insufficient

• Patients at risk of cardiovascular complications who may benefit from SGLT2 inhibition

Benefits

• Dual Mechanism of Action: Targets kidney glucose reabsorption and pancreatic insulin response simultaneously

• Effective Glycemic Control: Lowers fasting, postprandial glucose, and HbA1c levels

• Weight Neutral or Supportive: Empagliflozin may help with modest weight loss

• Low Hypoglycemia Risk: Especially when used without insulin or sulfonylureas

• Cardiovascular Support: Empagliflozin has demonstrated cardiovascular benefits in eligible patients

• Convenient Combination Therapy: Single tablet simplifies diabetes management

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Dosage and Administration

Adlina-EM Tablet 10 mg + 5 mg is typically taken once daily, in the morning, with or without food. The dose should be individualized by a healthcare professional based on patient response, kidney function, and overall glycemic control.

Regular monitoring of blood glucose, HbA1c, and renal function is recommended. Patients should maintain adequate hydration while using this medication.

Safety and Precautions

• Not indicated for Type 1 diabetes or diabetic ketoacidosis

• Use with caution in patients with renal impairment

• Increased risk of urinary tract and genital infections due to empagliflozin

• Mild gastrointestinal symptoms or headache may occur due to linagliptin

• Rare cases of ketoacidosis have been reported; seek medical attention if symptoms such as nausea, vomiting, abdominal pain, or shortness of breath occur

• Inform your healthcare provider about all medications and pre-existing medical conditions before starting treatment